ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016
Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- Identification of factors associated with non-adherence to oral endocrine therapy in breast cancer patients of low socioeconomic status: a single centre retrospective study.International journal of clinical pharmacy · 2026Article
- Differences in GLP-1 RA medication adherence across place-based variables in patients with diabetes living in Wisconsin.Journal of managed care & specialty pharmacy · 2025Article
- Drivers of Palliative Care and Hospice Use Among Patients With Advanced Lung Cancer.Cancer medicine · 2025Article
- Racial Disparities in the Prescribing of Guideline-Recommended Medications for Metastatic Prostate Cancer: A Retrospective Cohort Study.Prostate cancer · 2025Article
- The high costs of anticancer therapies in the USA: challenges, opportunities and progress.Nature reviews. Clinical oncology · 2024Review
- Adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic.International journal of clinical pharmacy · 2023Article
- Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review.Journal of breast cancer · 2023Article
- Effect of Phone Text Message Reminders on Compliance with Rabies Post-Exposure Prophylaxis following Dog Bites in Rural Kenya.Vaccines · 2023Article
- Association between low-income subsidies and inequities in orally administered antimyeloma therapy use.The American journal of managed care · 2023Article
- Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer.International journal of environmental research and public health · 2023Review
- Preventing metastatic recurrence in low-risk ER/PR + breast cancer patients-a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy.Breast cancer research and treatment · 2023Article
- Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer.Breast cancer research and treatment · 2023Article
- Adherence to Oral Anticancer Medications Among Women With Breast Cancer in Africa: A Scoping Review.JCO global oncology · 2023Article
- Identifying the predictors of adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status.Research square · 2022Article
- Article
- Factors associated with medication nonadherence among Medicare low-income subsidy beneficiaries with diabetes, hypertension, and/or heart failure.Journal of managed care & specialty pharmacy · 2021Article
- Octogenarians' Breast Cancer Is Associated with an Unfavorable Tumor Immune Microenvironment and Worse Disease-Free Survival.Cancers · 2021Article
- Cost sharing for breast cancer hormone therapy: How do dual eligible patients' copayment impact adherence.PloS one · 2021Article
- Breast Cancer Health Disparities in Hispanics/Latinas.Current breast cancer reports · 2020Article
- The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence.Cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Purpose To investigate the role of out-of-pocket cost supports through the Medicare Part D Low-Income Subsidy on disparities in breast cancer hormonal therapy persistence and adherence by race or ethnicity. Methods A nationwide cohort of women age ≥ 65 years with a breast cancer operation between 2006 and 2007 and at least one prescription filled for oral breast cancer hormonal therapy was identified from all Medicare D enrollees. The association of race or ethnicity with nonpersistence (90 consecutive days with no claims for a hormonal therapy prescription) and nonadherence (medication possession rate < 80%) was examined. Survival analyses were used to account for potential differences in age, comorbidity, or intensity of other treatments. Results Among the 25,111 women in the study sample, 77% of the Hispanic and 70% of the black women received a subsidy compared with 21% of the white women. By 2 years, 69% of black and 70% of Hispanic patients were persistent compared with 61% of white patients. In adjusted analyses, patients in all three unsubsidized race or ethnicity groups had greater discontinuation than subsidized groups (white patients: hazard ratio [HR], 1.83; 95% CI, 1.70 to 1.95; black patients: HR, 2.09; 95% CI, 1.73 to 2.51; Hispanic patients: HR, 3.00; 95% CI, 2.37 to 3.89). Racial or ethnic persistence disparities that were present for unsubsidized patients were not present or reversed among subsidized patients. All three subsidized race or ethnicity groups also had higher adherence than all three unsubsidized groups, although with the smallest difference occurring in black women. Conclusion Receipt of a prescription subsidy was associated with substantially improved persistence to breast cancer hormonal therapy among white, black, and Hispanic women and lack of racial or ethnic disparities in persistence. Given high subsidy enrollment among black and Hispanic women, policies targeted at low-income patients have the potential to also substantially reduce racial and ethnic disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.